BridgeBio Pharma, Inc. 8-K

What Happened
BridgeBio Pharma, Inc. announced recent business updates and reported its financial results for the fourth quarter and full year ended December 31, 2025. The company filed an 8-K (Item 2.02) on February 24, 2026 and furnished a press release with the full announcement as Exhibit 99.1 to the filing.

Key Details

• Filing date: February 24, 2026 (Current Report on Form 8-K).
• Reporting period: Fourth quarter and full year ended December 31, 2025.
• The company furnished a press release disclosing the results (Exhibit 99.1).
• Report signed by Thomas Trimarchi, Ph.D., President and Chief Financial Officer.

Why It Matters
This 8-K signals that BridgeBio has released its quarterly and annual earnings information, which can include key metrics investors care about—revenue, net income or loss, cash position, and any updated guidance or business developments. Retail investors should read the furnished press release (Exhibit 99.1) and any accompanying earnings materials to see the specific financial figures and management commentary, and watch for subsequent filings (e.g., 10-K or 10-Q) for complete audited financials and disclosures.